Kinzalkomb (Hydrochlorothiazide, Telmisartan)

Hydrochlorothiazide and Telmisartan, the active ingredients in Kinzalkomb, are a thiazide diuretic and an angiotensin II receptor blocker presented as a tablet for oral use. They are prescribed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Kinzalkomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable global distribution, supporting timely delivery and regulatory assistance for healthcare providers across multiple regions.

Kinzalkomb combines a thiazide diuretic and an angiotensin II receptor blocker to manage hypertension, the primary condition treated with this medication. - Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension. - Cardiovascular risk reduction: helps achieve target blood pressure, contributing to decreased risk of stroke and myocardial infarction in hypertensive individuals. - Renal protection in hypertension: assists in controlling blood pressure, which can slow progression of hypertensive nephropathy.

Kinzalkomb may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Increased urination - Electrolyte imbalance (e.g., low potassium) - Fatigue - Cough

Serious or Rare Side Effects: - Severe allergic reaction (angioedema) - Acute kidney injury - Hyperkalemia - Pancreatitis - Hepatic dysfunction - Blood disorders such as neutropenia

Before initiating Kinzalkomb, several safety considerations should be reviewed. - Monitor blood pressure: ensure adequate control and avoid hypotension. - Assess renal function: check serum creatinine and eGFR regularly. - Check electrolytes: especially potassium and sodium levels. - Avoid in severe hepatic impairment: use only if benefits outweigh risks. - Use caution in diabetes: monitor glucose as diuretic may affect glycemic control. - Store at room temperature: keep in the original pack, protect from moisture.

Kinzalkomb can interact with several medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Aliskiren: combined use may increase risk of renal impairment. - Potassium supplements or potassium‑sparing diuretics: risk of hyperkalemia. - ACE inhibitors: additive effect on potassium levels. - Lithium: increased lithium concentrations. - NSAIDs: may reduce antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: additive blood‑pressure lowering may require dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole): may increase telmisartan levels. - Additional diuretics: monitor for electrolyte disturbances. - Antidiabetic drugs: possible need for dose modification. - NSAIDs (monitor renal function): use with caution and monitor kidney parameters.